Arthur M. Cohen & Associates LLC raised its holdings in Edwards Lifesciences Corp (NYSE:EW) by 5.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,906 shares of the medical research company’s stock after buying an additional 400 shares during the period. Edwards Lifesciences accounts for about 0.5% of Arthur M. Cohen & Associates LLC’s portfolio, making the stock its 27th largest holding. Arthur M. Cohen & Associates LLC’s holdings in Edwards Lifesciences were worth $1,513,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. BlackRock Inc. increased its stake in Edwards Lifesciences by 7.4% in the 4th quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock valued at $2,516,802,000 after buying an additional 1,128,082 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in Edwards Lifesciences by 21,360.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock valued at $69,000 after buying an additional 10,587,326 shares during the last quarter. FMR LLC increased its stake in Edwards Lifesciences by 28.9% in the 4th quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock valued at $1,160,540,000 after buying an additional 1,700,199 shares during the last quarter. Jennison Associates LLC increased its stake in Edwards Lifesciences by 184.7% in the 4th quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock valued at $629,855,000 after buying an additional 2,667,749 shares during the last quarter. Finally, Norges Bank acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $559,646,000. Hedge funds and other institutional investors own 84.43% of the company’s stock.

Several equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research note on Thursday, May 9th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Jefferies Financial Group lifted their price objective on shares of Edwards Lifesciences from $195.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. BTIG Research reissued a “hold” rating on shares of Edwards Lifesciences in a research report on Wednesday, April 24th. Finally, Raymond James decreased their price objective on shares of Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating for the company in a research report on Wednesday, April 24th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $187.00.

Shares of EW opened at $177.25 on Thursday. Edwards Lifesciences Corp has a one year low of $134.38 and a one year high of $197.86. The stock has a market capitalization of $37.20 billion, a PE ratio of 37.71, a PEG ratio of 2.28 and a beta of 0.85. The company has a quick ratio of 2.69, a current ratio of 3.66 and a debt-to-equity ratio of 0.17.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.23 by $0.09. The business had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. Edwards Lifesciences’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.22 EPS. On average, research analysts forecast that Edwards Lifesciences Corp will post 5.28 earnings per share for the current fiscal year.

In related news, VP Catherine M. Szyman sold 1,474 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 21st. The shares were sold at an average price of $176.34, for a total transaction of $259,925.16. Following the completion of the sale, the vice president now owns 15,905 shares of the company’s stock, valued at approximately $2,804,687.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Larry L. Wood sold 6,716 shares of Edwards Lifesciences stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $170.82, for a total transaction of $1,147,227.12. Following the sale, the vice president now directly owns 122,366 shares of the company’s stock, valued at approximately $20,902,560.12. The disclosure for this sale can be found here. Insiders have sold a total of 148,411 shares of company stock valued at $26,189,586 in the last ninety days. 1.63% of the stock is currently owned by insiders.

WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://theolympiareport.com/2019/05/16/arthur-m-cohen-associates-llc-acquires-400-shares-of-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.